Akèy › Neuroblastom › Massachusetts
Etid klinik pou Neuroblastom nan Massachusetts
13 etid pou Neuroblastom ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
Jiska laj 30 · Tout sèks · Mizajou Oct 2, 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Ap rekrite
Tout laj · Tout sèks · Mizajou Oct 1, 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
Ap rekriteFaz 1
9 Months – 30 Years · Tout sèks · Mizajou Sep 3, 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
365 Days – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 2 a 21 · Tout sèks · Mizajou Aug 11, 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 1 a 30 · Tout sèks · Mizajou Jul 22, 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Ap rekriteFaz 2
Laj 1 a 31 · Tout sèks · Mizajou Jul 20, 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Jul 14, 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
Ap rekriteEtid obsèvasyon
31 Days – 99 Years · Tout sèks · Mizajou Mar 23, 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Jiska laj 17 · Tout sèks · Mizajou Feb 10, 2026 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
12 Months – 29 Years · Tout sèks · Mizajou Dec 26, 2025 · NCT06803875Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.